Despite researchers’ efforts in understanding the impact of somatic gene mutations in KRAS and TP53 on bioenergetics, cell proliferation and survival in CRC, the dependence of these mechanisms on the mutational status of the tumor still needs elucidation. This evidence concerns the gene KRAS and colorectal carcinoma.